JP7060579B2 - 抗微生物化合物 - Google Patents

抗微生物化合物 Download PDF

Info

Publication number
JP7060579B2
JP7060579B2 JP2019508251A JP2019508251A JP7060579B2 JP 7060579 B2 JP7060579 B2 JP 7060579B2 JP 2019508251 A JP2019508251 A JP 2019508251A JP 2019508251 A JP2019508251 A JP 2019508251A JP 7060579 B2 JP7060579 B2 JP 7060579B2
Authority
JP
Japan
Prior art keywords
compound
independently
group
alkenyl
linear
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2019508251A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019527724A5 (enExample
JP2019527724A (ja
Inventor
スチュアート・コッカリル
Original Assignee
ザ・ユニバーシティ・オブ・ダラム
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ・ユニバーシティ・オブ・ダラム filed Critical ザ・ユニバーシティ・オブ・ダラム
Publication of JP2019527724A publication Critical patent/JP2019527724A/ja
Publication of JP2019527724A5 publication Critical patent/JP2019527724A5/ja
Application granted granted Critical
Publication of JP7060579B2 publication Critical patent/JP7060579B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/24—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/24—Oxygen atoms
    • C07D243/26—Preparation from compounds already containing the benzodiazepine skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2019508251A 2016-08-15 2017-08-15 抗微生物化合物 Expired - Fee Related JP7060579B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1613942.0 2016-08-15
GBGB1613942.0A GB201613942D0 (en) 2016-08-15 2016-08-15 An antimicrobial compound
PCT/GB2017/052393 WO2018033714A1 (en) 2016-08-15 2017-08-15 An antimicrobial compound

Publications (3)

Publication Number Publication Date
JP2019527724A JP2019527724A (ja) 2019-10-03
JP2019527724A5 JP2019527724A5 (enExample) 2020-09-24
JP7060579B2 true JP7060579B2 (ja) 2022-04-26

Family

ID=56985954

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019508251A Expired - Fee Related JP7060579B2 (ja) 2016-08-15 2017-08-15 抗微生物化合物

Country Status (5)

Country Link
US (1) US11247973B2 (enExample)
EP (1) EP3497096B1 (enExample)
JP (1) JP7060579B2 (enExample)
GB (1) GB201613942D0 (enExample)
WO (1) WO2018033714A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201911944D0 (en) 2019-08-20 2019-10-02 Reviral Ltd Pharmaceutical compounds
GB201915273D0 (en) 2019-10-22 2019-12-04 Reviral Ltd Pharmaceutical compounds
GB201915932D0 (en) 2019-11-01 2019-12-18 Reviral Ltd Pharmaceutical compounds
GB202010408D0 (en) 2020-07-07 2020-08-19 Reviral Ltd Pharmaceutical compounds
GB202010409D0 (en) 2020-07-07 2020-08-19 Reviral Ltd Pharmaceutical compounds
GB202102602D0 (en) 2021-02-24 2021-04-07 Reviral Ltd Pharmaceutical compounds
WO2024252355A1 (en) 2023-06-08 2024-12-12 Pfizer Inc. Pediatric dosing regimens comprising a fusion inhibitor for the treatment of rsv
WO2025120500A1 (en) 2023-12-06 2025-06-12 Pfizer Inc. Benzodiazepine compounds as n-protein inhibitors
WO2025153942A1 (en) 2024-01-16 2025-07-24 Pfizer Inc. Benzodiazepine pyrazolo carboxamides as n-protein inhibitors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000510155A (ja) 1996-06-28 2000-08-08 メルク エンド カンパニー インコーポレーテッド 医薬製剤

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5004741A (en) * 1984-06-26 1991-04-02 Merck & Co., Inc. Methods of antagonizing CCK or gastrin with benzodiazepine analogs
US4820834A (en) 1984-06-26 1989-04-11 Merck & Co., Inc. Benzodiazepine analogs
US5428031A (en) * 1991-12-03 1995-06-27 Merck & Co., Inc. Methods of treating cardiac arrhythmia
US5426185A (en) * 1993-11-22 1995-06-20 Merck & Co., Inc. Antiarrhythmic benzodiazepines
AU3400797A (en) * 1996-06-27 1998-01-14 Merck & Co., Inc. A method for treating meniere's disease
US5776930A (en) * 1996-06-28 1998-07-07 Merck & Company, Inc. Pharmaceutical preparation
US5817658A (en) * 1997-03-14 1998-10-06 Merck & Company, Inc. Method for treating Meniere's disease
BR9913226A (pt) * 1998-09-01 2001-05-22 Innogenetics Nv Benzodiazepinas e derivados de benzotiazepinas e peptìdios de hbsag ligados a anexinas, suas composições e uso
AU2003267587B2 (en) 2002-09-20 2010-05-20 Arrow Therapeutics Limited Benzodiazepine derivatives and pharmaceutical compositions containing them
GB0406282D0 (en) 2004-03-19 2004-04-21 Arrow Therapeutics Ltd Therapeutic compounds
GB0406279D0 (en) * 2004-03-19 2004-04-21 Arrow Therapeutics Ltd Therapeutic compounds
GB0406280D0 (en) * 2004-03-19 2004-04-21 Arrow Therapeutics Ltd Chemical compounds
WO2005090319A1 (en) 2004-03-19 2005-09-29 Arrow Therapeutics Limited Process for preparing benzodiazepines
AU2005336627A1 (en) * 2005-09-19 2007-03-29 Arrow Therapeutics Limited Benzodiazepine derivatives for treating hepatitis C infection
AU2007321977A1 (en) * 2006-11-21 2008-05-29 Novartis Ag Stable parenteral formulation containing a RSV inhibitor of a benzodiazepine structure
WO2011151652A1 (en) * 2010-06-03 2011-12-08 Arrow Therapeutics Limited Benzodiazepine compounds useful for the treatment of hepatitis c
WO2011151651A1 (en) * 2010-06-03 2011-12-08 Arrow Therapeutics Limited Benzodiazepine compounds useful for the treatment of hepatitis c
GB201506448D0 (en) * 2015-04-16 2015-06-03 Univ Durham An antimicrobial compound
MY197231A (en) * 2015-07-22 2023-06-06 Enanta Pharm Inc Benzodiazepine derivatives as rsv inhibitors
GB201911944D0 (en) * 2019-08-20 2019-10-02 Reviral Ltd Pharmaceutical compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000510155A (ja) 1996-06-28 2000-08-08 メルク エンド カンパニー インコーポレーテッド 医薬製剤

Also Published As

Publication number Publication date
US20210017138A1 (en) 2021-01-21
EP3497096A1 (en) 2019-06-19
US11247973B2 (en) 2022-02-15
GB201613942D0 (en) 2016-09-28
EP3497096B1 (en) 2021-11-10
WO2018033714A1 (en) 2018-02-22
JP2019527724A (ja) 2019-10-03

Similar Documents

Publication Publication Date Title
US11247973B2 (en) Antiviral benzodiazepine compounds
AU2020267169B2 (en) Processes of making and crystalline forms of a MDM2 inhibitor
CN112218859B (zh) 蛋白水解调节剂及相关使用方法
JP6676602B2 (ja) 上皮成長因子受容体キナーゼ阻害剤の塩
JP6882299B2 (ja) 多環式ｔｌｒ７／８アンタゴニスト及び免疫障害の治療におけるそれらの使用
EP3065738B1 (en) Compositions and methods for modulating farnesoid x receptors
CN104302178B (zh) 表皮生长因子受体激酶抑制剂的固体形式
CN114409653A (zh) 一种桥环并嘧啶并环类化合物及其用途
KR20170032330A (ko) Ｃ-Ｍｅｔ 억제제의 결정질 유리 염기 또는 이의 결정질 산 염, 및 이들의 제조방법 및 용도
CN101778840A (zh) ((1s)-1-(((2s)-2-(5-(4’-(2-((2s)-1-((2s)-2-((甲氧羰基)氨基)-3-甲基丁酰基)-2-吡咯烷基)-1h-咪唑-5-基)-4-联苯基)-1h-咪唑-2-基)-1-吡咯烷基)羰基)-2-甲基丙基)氨基甲酸甲酯二盐酸盐的晶型
CN101903371A (zh) N-(叔-丁氧基羰基)-3-甲基-l-缬氨酰-(4r)-4-((7-氯-4-甲氧基-1-异喹啉基)氧基)-n-((1r，2s)-1-((环丙基磺酰基)氨甲酰基)-2-乙烯基环丙基)-l-脯氨酰胺的晶型
CN107922418A (zh) 抗微生物化合物及制备和使用所述化合物的方法
EP2504331B1 (en) Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use
JP2019511568A (ja) 免疫調節剤としての三環式化合物
CN109516990B (zh) 嘧啶并三氮唑类化合物、其制备方法和用途
WO2019078116A1 (ja) 甘味受容体アンタゴニスト
KR20230107280A (ko) 빈혈 치료용 vhl 억제제로서 1-(2-(4-시클로프로필-1h-1,2,3-트리아졸-1-일)아세틸)-4-히드록시피롤리딘-2-카르복사미드 유도체
JP2025539698A (ja) 新規シアノピリジンｋｈｋ阻害剤化合物
WO2025016439A1 (zh) 用作cdk2/4蛋白激酶抑制剂的化合物及其应用
HK40039964A (en) Tricyclic compounds

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200814

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200814

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210719

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211014

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220322

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220414

R150 Certificate of patent or registration of utility model

Ref document number: 7060579

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees